Compare NEA & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NEA | WGS |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.7B |
| IPO Year | 2002 | 2020 |
| Metric | NEA | WGS |
|---|---|---|
| Price | $10.34 | $71.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $93.50 |
| AVG Volume (30 Days) | ★ 2.3M | 711.4K |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $427,539,000.00 |
| Revenue This Year | N/A | $12.70 |
| Revenue Next Year | N/A | $24.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.97 |
| 52 Week Low | $9.53 | $32.21 |
| 52 Week High | $11.90 | $170.87 |
| Indicator | NEA | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 56.07 | 50.50 |
| Support Level | $9.72 | $68.55 |
| Resistance Level | $11.72 | $73.04 |
| Average True Range (ATR) | 0.16 | 5.57 |
| MACD | 0.07 | 0.65 |
| Stochastic Oscillator | 91.35 | 89.60 |
Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities. The company invest in Transportation, Utilities, Healthcare, Education and Civics, and other sectors, with maximum investment in Transportation.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.